Expression of mitochondrial regulators PGC1a and TFAM as putative markers of subtype and chemoresistance in epithelial ovarian carcinoma

PLoS ONE

Volumn 9, Issue 9, 2014, Pages

  Gabrielson, Marike ^a   Bjorklund M Y ^a   Carlson, Joseph ^a,b   Shoshan, Maria ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

DNA BINDING PROTEIN; GLYCOGEN; MITOCHONDRIAL PROTEIN; PPARGC1A PROTEIN, HUMAN; TFAM PROTEIN, HUMAN; TRANSCRIPTION FACTOR; TUMOR MARKER;

ADENOCARCINOMA, CLEAR CELL; ADULT; AGED; CYSTADENOCARCINOMA, SEROUS; DISEASE COURSE; DRUG RESISTANCE; FEMALE; GENETICS; HUMAN; METABOLISM; MIDDLE AGED; OVARIAN NEOPLASMS; PATHOLOGY; PROGNOSIS; TUMOR CELL LINE; VERY ELDERLY;

ADENOCARCINOMA, CLEAR CELL; ADULT; AGED; AGED, 80 AND OVER; CELL LINE, TUMOR; CYSTADENOCARCINOMA, SEROUS; DISEASE PROGRESSION; DNA-BINDING PROTEINS; DRUG RESISTANCE, NEOPLASM; FEMALE; GLYCOGEN; HUMANS; MIDDLE AGED; MITOCHONDRIAL PROTEINS; OVARIAN NEOPLASMS; PROGNOSIS; TRANSCRIPTION FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84930989633     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0107109     Document Type: Article

References (45)

1. Lengyel E (2010) Ovarian cancer development and metastasis. The American journal of pathology 177: 1053-1064.
2. Coleman RL, Monk BJ, Sood AK, Herzog TJ (2013) Latest research and treatment of advanced-stage epithelial ovarian cancer. Nat Rev Clin Oncol 10: 211-224.
3. Shih Ie M, Kurman RJ (2004) Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol 164: 1511-1518.
4. Gurung A, Hung T, Morin J, Gilks CB (2013) Molecular abnormalities in ovarian carcinoma: clinical, morphological and therapeutic correlates. Histopathology 62: 59-70.
5. Winter WE 3rd, Maxwell GL, Tian C, Carlson JW, Ozols RF, et al. (2007) Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol 25: 3621-3627.
6. du Bois A, Luck HJ, Meier W, Adams HP, Mobus V, et al. (2003) A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 95: 1320-1329.
7. Takano M, Kikuchi Y, Yaegashi N, Kuzuya K, Ueki M, et al. (2006) Clear cell carcinoma of the ovary: a retrospective multicentre experience of 254 patients with complete surgical staging. Br J Cancer 94: 1369-1374.
8. Hanahan D,Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144: 646-674.
9. Ward PS, Thompson CB (2012) Metabolic reprogramming: a cancer hallmark even warburg did not anticipate. Cancer cell 21: 297-308.
10. DeBerardinis RJ, Mancuso A, Daikhin E, Nissim I, Yudkoff M, et al. (2007) Beyond aerobic glycolysis: transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis. Proc Natl Acad Sci U S A 104: 19345-19350.
11. Hardie DG (2011) AMP-activated protein kinase: an energy sensor that regulates all aspects of cell function. Genes Dev 25: 1895-1908.
12. Finck BN, Kelly DP (2006) PGC-1 coactivators: inducible regulators of energy metabolism in health and disease. J Clin Invest 116: 615-622.
13. Canto C, Auwerx J (2009) PGC-1alpha, SIRT1 and AMPK, an energy sensing network that controls energy expenditure. Current opinion in lipidology 20: 98-105.
14. Aquilano K, Vigilanza P, Baldelli S, Pagliei B, Rotilio G, et al. (2010) Peroxisome proliferator-activated receptor gamma co-activator 1alpha (PGC- 1alpha) and sirtuin 1 (SIRT1) reside in mitochondria: possible direct function in mitochondrial biogenesis. J Biol Chem 285: 21590-21599.
15. Ventura-Clapier R, Garnier A, Veksler V (2008) Transcriptional control of mitochondrial biogenesis: the central role of PGC-1alpha. Cardiovasc Res 79: 208-217.
16. Virbasius JV, Scarpulla RC (1994) Activation of the human mitochondrial transcription factor A gene by nuclear respiratory factors: a potential regulatory link between nuclear and mitochondrial gene expression in organelle biogenesis. Proc Natl Acad Sci U S A 91: 1309-1313.
17. Kaufman BA, Durisic N, Mativetsky JM, Costantino S, Hancock MA, et al. (2007) The mitochondrial transcription factor TFAM coordinates the assembly of multiple DNA molecules into nucleoid-like structures. Mol Biol Cell 18: 3225-3236.
18. Kanki T, Ohgaki K, Gaspari M, Gustafsson CM, Fukuoh A, et al. (2004) Architectural role of mitochondrial transcription factor A in maintenance of human mitochondrial DNA. Mol Cell Biol 24: 9823-9834.
19. Lu B, Lee J, Nie X, Li M, Morozov YI, et al. (2013) Phosphorylation of human TFAM in mitochondria impairs DNA binding and promotes degradation by the AAA+ Lon protease. Mol Cell 49: 121-132.
20. Matsushima Y, Goto Y, Kaguni LS (2010) Mitochondrial Lon protease regulates mitochondrial DNA copy number and transcription by selective degradation of mitochondrial transcription factor A (TFAM). Proc Natl Acad Sci U S A 107: 18410-18415.
21. Austin S, St-Pierre J (2012) PGC1alpha and mitochondrial metabolism- emerging concepts and relevance in ageing and neurodegenerative disorders. J Cell Sci 125: 4963-4971.
22. Lettieri Barbato D, Baldelli S, Pagliei B, Aquilano K, Ciriolo MR (2012) Caloric Restriction and the Nutrient-Sensing PGC-1alpha in Mitochondrial Homeostasis: New Perspectives in Neurodegeneration. Int J Cell Biol 2012: 759583.
23. Handschin C, Spiegelman BM (2006) Peroxisome proliferator-activated receptor gamma coactivator 1 coactivators, energy homeostasis, and metabolism. Endocr Rev 27: 728-735.
24. Klinge CM (2008) Estrogenic control of mitochondrial function and biogenesis. J Cell Biochem 105: 1342-1351.
25. Tcherepanova I, Puigserver P, Norris JD, Spiegelman BM, McDonnell DP (2000) Modulation of estrogen receptor-alpha transcriptional activity by the coactivator PGC-1. J Biol Chem 275: 16302-16308.
26. Kobel M, Kalloger SE, Boyd N, McKinney S, Mehl E, et al. (2008) Ovarian carcinoma subtypes are different diseases: implications for biomarker studies. PLoS Med 5: e232.
27. Wintzell M, Lofstedt L, Johansson J, Pedersen AB, Fuxe J, et al. (2012) Repeated cisplatin treatment can lead to a multiresistant tumor cell population with stem cell features and sensitivity to 3-bromopyruvate. Cancer Biol Ther 13: 1454-1462.
28. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402-408.
29. Lau KM, Mok SC, Ho SM (1999) Expression of human estrogen receptor-alpha and -beta, progesterone receptor, and androgen receptor mRNA in normal and malignant ovarian epithelial cells. Proc Natl Acad Sci U S A 96: 5722-5727.
30. Hua W, Christianson T, Rougeot C, Rochefort H, Clinton GM (1995) SKOV3 ovarian carcinoma cells have functional estrogen receptor but are growthresistant to estrogen and antiestrogens. J Steroid Biochem Mol Biol 55: 279-289.
31. Ohkawa K, Amasaki H, Terashima Y, Aizawa S, Ishikawa E (1977) Clear cell carcinoma of the ovary: light and electron microscopic studies. Cancer 40: 3019-3029.
32. Anglesio MS, Carey MS, Kobel M, Mackay H, Huntsman DG, et al. (2011) Clear cell carcinoma of the ovary: a report from the first Ovarian Clear Cell Symposium, June 24th, 2010. Gynecol Oncol 121: 407-415.
33. Zhang Y, Ba Y, Liu C, Sun G, Ding L, et al. (2007) PGC-1alpha induces apoptosis in human epithelial ovarian cancer cells through a PPARgammadependent pathway. Cell Res 17: 363-373.
34. Feilchenfeldt J, Brundler MA, Soravia C, Totsch M, Meier CA (2004) Peroxisome proliferator-activated receptors (PPARs) and associated transcription factors in colon cancer: reduced expression of PPARgamma-coactivator 1 (PGC- 1). Cancer Lett 203: 25-33.
35. Deblois G, St-Pierre J, Giguere V (2013) The PGC-1/ERR signaling axis in cancer. Oncogene 32: 3483-3490.
36. Zhao Y, Butler EB, Tan M (2013) Targeting cellular metabolism to improve cancer therapeutics. Cell Death Dis 4: e532.
37. Berndtsson M, Hagg M, Panaretakis T, Havelka AM, Shoshan MC, et al. (2007) Acute apoptosis by cisplatin requires induction of reactive oxygen species but is not associated with damage to nuclear DNA. Int J Cancer 120: 175-180.
38. Ray PD, Huang BW, Tsuji Y (2012) Reactive oxygen species (ROS) homeostasis and redox regulation in cellular signaling. Cell Signal 24: 981-990.
39. Guo J, Zheng L, Liu W, Wang X, Wang Z, et al. (2011) Frequent truncating mutation of TFAM induces mitochondrial DNA depletion and apoptotic resistance in microsatellite-unstable colorectal cancer. Cancer research 71: 2978-2987.
40. Cooper CE, Nicholls P, Freedman JA (1991) Cytochrome c oxidase: structure, function, and membrane topology of the polypeptide subunits. Biochem Cell Biol 69: 586-607.
41. Goto A, Matsushima Y, Kadowaki T, Kitagawa Y (2001) Drosophila mitochondrial transcription factor A (d-TFAM) is dispensable for the transcription of mitochondrial DNA in Kc167 cells. Biochem J 354: 243-248.
42. Chakrabarty S, D'Souza RR, Kabekkodu SP, Gopinath PM, Rossignol R, et al. (2014) Upregulation of TFAM and mitochondria copy number in human lymphoblastoid cells. Mitochondrion.
43. Sieh W, Kobel M, Longacre TA, Bowtell DD, deFazio A, et al. (2013) Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study. Lancet Oncol 14: 853-862.
44. Faratian D, Zweemer AJ, Nagumo Y, Sims AH, Muir M, et al. (2011) Trastuzumab and pertuzumab produce changes in morphology and estrogen receptor signaling in ovarian cancer xenografts revealing new treatment strategies. Clin Cancer Res 17: 4451-4461.
45. Hardie DG, Alessi DR (2013) LKB1 and AMPK and the cancer-metabolism link - ten years after. BMC Biol 11: 36.